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Abstract.
We propose a stochastic model that accounts for the growth, catastrophe and
rescue processes of steady state microtubules assembled from MAP-free tubulin in the
possible presence of a microtubule associated drug. As an example for the latter, we
both experimentally and theoretically study the perturbation of microtubule dynamic
instability by S-methyl-D-DM1, a synthetic derivative of the microtubule-targeted
agent maytansine and a potential anticancer agent. Our model predicts that among
drugs that act locally at the microtubule tip, primary inhibition of the loss of GDP
tubulin results in stronger damping of microtubule dynamics than inhibition of GTP
tubulin addition. On the other hand, drugs whose action occurs in the interior of the
microtubule need to be present in much higher concentrations to have visible effects.
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1. Introduction
Microtubules are hollow and flexible cylindrical polymers of the protein tubulin that
form a major component of the cytoskeleton of eukaryotic cells. They play a central
role in maintenance of structural stability of the cell, intracellular vesicle transport and
chromosome separation during mitosis. The polymerization of tubulin into microtubules
and the subsequent catastrophic depolymerization have been studied extensively both
experimentally and theoretically, see [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14] for just
a few examples. The prevailing model to explain dynamic instability, the lateral cap
model, is that a cap of GTP tubulin at the growing tip is required for stability of the
polymer and that a loss of this GTP cap results in dramatic shortening of microtubules
[15].
In the paper [14] we proposed a partial differential equation model inspired by
dynamics of size-structured populations. The variables of that continuous model are
length distributions of microtubules and the amounts of free tubulin. The major
reactions are the polymerization of free GTP tubulin, the hydrolysis of assembled GTP
tubulin to GDP tubulin, the decay and rescue of microtubules without a GTP cap
and the recycling of free GDP tubulin to GTP tubulin. The model conserves the
total amount of tubulin in all its forms. In addition, we allowed for the nucleation
of fresh microtubules at certain specified (short) lengths. With a small number of
parameters that have clear biochemical interpretations, we were able to reproduce
commonly observed experimental behaviors, such as oscillations in the amount of tubulin
assembled into microtubules. Obviously, the continuous model is not expected to
reproduce the lengths of individual microtubules. To this end, in this paper we present a
stochastic discrete model of microtubule dynamic instability and compare its predictions
to observations of microtubule lengths from in vitro experiments that also include the
presence of a dynamic instability suppressing drug.
Stochastic discrete models of biopolymer dynamics have been investigated, among
others, in [4, 5, 16, 17, 18, 12, 13, 19, 20]. Bolterauer et al. [4, 5] introduced a stochastic
model to study the dynamics of free microtubules using the master equation approach.
They showed that in the continuum limit the microtubule length distribution follows a
bell-shaped curve. Mishra et al. [20] applied a similar technique to elaborate the effect
of catastrophe-suppressing drugs on the dynamic instability of microtubules. They
assumed that drug molecules bind rapidly to free tubulin in the solution. Then, the
drug-tubulin complexes bind to the growing tips of the microtubules and reduce the
catastrophe frequency by stabilizing the microtubule caps. They also assumed that
the drug-tubulin complex has a lower attachment rate than drug-free tubulin. As a
result, one would expect to observe shorter drug-treated microtubules in the steady
state. While they found a qualitative reduction in catastrophe frequency, surprisingly,
they found that the drug-treated microtubules have the same length distribution as free
microtubules.
Here we present a stochastic model that represents the same set of reactions as our
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continuous model in [14], except for the nucleation of fresh microtubules which is an
unnecessary complication for the case studied here. Similar to other stochastic models
[16, 17, 12, 13, 19, 20], our underlying model that describes microtubule dynamics
without drugs is based on an effective two-state model, switching between a growing
and shortening state. As in [14] and in contrast to other works such as [16, 20],
we couple the growth velocity of microtubules to the amount of free GTP tubulin
and the model is constructed so as to preserve the total amount of tubulin in all its
forms. Following [8], we include hydrolysis events of two kinds, namely scalar hydrolysis
(conversion of bound GTP tubulin to GDP tubulin with equal probability) and vectorial
hydrolysis (the probability is enhanced by a GDP tubulin neighbor). Furthermore, in
contrast to previous models that simulate one microtubule at a time, we simulate several
microtubules at the same time. This enables us to capture a more realistic situation
similar to one in experiments. Last but not least, a great advantage of our model is
that it can be implemented straightforwardly with the help of the Gillespie Algorithm
[21], an exact simulation method for stochastic chemical reactions. Our goal is to
explain individual length observations of microtubules growing without microtubule
associated proteins (MAPs) in vitro or length constraints (as in [17]). Moreover, we
investigate the effects of tubulin-binding drugs on microtubule dynamic instability.
These drugs belong roughly to one of two classes, namely those that bind to assembled
microtubules and those that bind to free tubulin [22]. This difference in behaviors
may be due to conformational changes of the α/β-tubulin heterodimer [23] (the tubulin
unit from now on) upon incorporation into the microtubule lattice that expose or hide
the binding site for the drug molecule. Apart from these different binding modes, the
effects on the microtubule reactions can also differ [24]. Some drugs mainly slow down
microtubule formation while others mainly prevent microtubule decay. This is not a
strict dichotomy in that some drugs can have multiple actions, depending on their
concentration. For example, vinblastine inhibits microtubule formation at high drug
concentrations, and inhibits microtubule decay at low concentrations [22]. Moreover,
there are multiple action mechanisms of drugs, for example either by preventing addition
of GTP tubulin,loss of GDP tubulin from an exposed tip or by preventing the hydrolysis
of GTP tubulin incorporated in the microtubule. In any case, within a living cell exposed
to anti-mitotic agents, mitosis cannot be completed and the cell dies. This property of
tubulin-binding drugs leads to many successful anti-cancer chemotherapeutics such as
paclitaxel, vincristine, vinblastine to name but a few. Maytansine and its derivatives
are known to suppress microtubule dynamics in vitro and in cells [25]. As an example,
we focus on the potential anticancer agent S-methyl-D-DM1, a synthetic derivative of
the microtubule-binding agent maytansine. Antibody-DM1 conjugates are currently
under clinical trials with promising results [26]. In our model, drugs act by decelerating
(or accelerating) binding or release reactions by a certain factor. Thus the strength
of the action can be quantified and linked to the binding energy through the standard
Arrhenius relation.
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2. The stochastic model
We consider a linear model of the microtubule and disregard the fact that it actually
consists of 13-17 protofilaments arranged in a helical lattice. Tubulin can be added to
the microtubule in form of small oligomers of varying sizes [27].
Let m ≥ 1 be the number of dynamic microtubules. The state of each microtubule
is represented as a word vk = (. . . , vk2 , v
k
1 , v
k
0), k = 1, . . . ,m on the binary alphabet
{0, 1} where the letter 1 stands for a position occupied by a GTP tubulin unit and 0
stands for a position occupied by a GDP tubulin unit. The length of the microtubule
vk is denoted by |vk|. The number of GTP tubulin units within vk is denoted by I(vk).
The “tip” of the microtubule is the letter vk0 and this is the only position where growth
or shrinkage can occur. Consecutive strings of 0s and 1s are called GDP zones and
GTP zones, respectively. The number of boundaries between such zones is denoted by
B(vk). The numbers of free GTP tubulin and GDP tubulin are denoted by NT and
ND, respectively. These numbers can be converted to and from concentrations, if the
volume in which the reactions take place is given. The following reactions occur (see
also Figure 1).
(i) Growth by attachment of GTP tubulin(s)
vk 7→ [vk 1 . . . 1︸ ︷︷ ︸
l
], NT 7→ NT − l,
at rate (derived from mass action kinetics)
λNT (vk0 + p(1− vk0)). (1)
Notice that every microtubule has its own growth reaction so that there are m
of them. The number of added GTP tubulin units l can be set to a fixed value
(say, 1) or drawn from a Poisson distribution with parameter L. The dimensionless
parameter p ≥ 0 is the propensity of a rescue event when a GDP tubulin unit at
the tip of the microtubule is exposed. In the simplest case, p = 1, attachment of a
new GTP tubulin is independent of the tip status.
(ii) Loss of a GDP tubulin (when the tip is in the state 0)
vk 7→ (. . . , vk2 , vk1), ND 7→ ND + 1,
at rate µGDP (1− vk0). Again there are m such shrinking reactions.
(iii) Loss of a GTP tubulin (when the tip is in the state 1)
vk 7→ (. . . , vk2 , vk1), NT 7→ NT + 1,
at rate µGTPv
k
0 .
(iv) Hydrolytic conversion of a bound GTP tubulin vk
∗ 7→ v˜k∗ at rate δsc
∑m
k=1 I(v
k).
The index k∗ is chosen uniformly in the set {1, . . . ,m} and a random position of
vk
∗
that is occupied by 1 is changed to 0 (this hydrolysis mechanism is called scalar
hydrolysis in [8]).
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(v) Hydrolytic conversion of a bound GTP tubulin vk
∗ 7→ v˜k∗ at rate δvec
∑m
k=1B(v
k).
Again, the index k∗ is chosen uniformly in the set {1, . . . ,m} and the word v˜k∗
is created by selecting randomly a position of vk
∗
where a 1 neighbors a 0 and
changing that 1 to 0 (this hydrolysis mechanism is called vectorial hydrolysis in [8],
see Figure 2, left panel).
(vi) Recycling of free GDP tubulin to GTP tubulin
ND 7→ ND − 1, NT 7→ NT + 1,
at rate κND. It is assumed that a sufficient amount of chemical energy in the form
of free GTP is always present.
This scheme can be simplified by setting some parameter values to zero. For
example, one may disregard the possibility of a bound GTP tubulin to be lost again
(µGTP = 0, cf. [8]), although other authors argue that this may take place in up to 90%
of all binding events [28]. The addition size l can be selected to be constant 1. The
hydrolysis reaction (iv) picks any bound GTP tubulin and changes it to a GDP tubulin,
thereby creating islands of GTP tubulin within the length of the microtubule. That
this is possible and important for the rescue process was recently shown by Dimitrov
et al. [29]. Both hydrolysis mechanisms in concert provide an indirect coupling of the
hydrolysis reaction to the addition of new GTP tubulin units [8].
Tubulin-binding drugs can bind to tubulin in one of two states, whether it is free
or bound within a microtubule. Here, we consider drugs that suppress microtubule
dynamic instability by specifically binding to microtubules. For every microtubule
encoded by a word v, we introduce a second wordw = (. . . , w2, w1, w0) over the alphabet
{0, 1} (the drug state), of equal length as v. Here wi = 1, if the tubulin unit at position
vi is occupied by a drug molecule and wi = 0 otherwise. There are binding events of
drug molecules to unoccupied sites and release of drug molecules from the microtubule.
Let E(w) be the number of available sites for drug binding and let F (w) be the number
of drug occupied sites. The latter is always the sum of the entries 1 in w while the
former may be only a subset of entries 0 in w. We have the association and dissociation
events
(vii) Binding of drug to tubulin units within the microtubule
wk
∗ 7→ w˜k∗ , D 7→ D − 1,
at rate ρD
∑m
k=1E(w
k). The new word w˜k
∗
is obtained by selecting randomly one
letter 0 among the sites available for binding and changing it to 1. This set may be
the set of all entries 0 or the entries 0 that are within a certain distance from the
tips or the unoccupied tips alone.
(viii) Release of drug from the occupied sites of the microtubule
wk
∗ 7→ w˜k∗ , D 7→ D + 1,
at rate σ
∑m
k=1 F (w
k). The new word w˜k
∗
is obtained by changing one randomly
selected letter 1 in any of the drug words to 0.
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The reactions (i)–(vi) have the same outcomes as far as changes in numerical quantities
are concerned, however the rates of reactions (i), (ii) and (iii) have a more complicated
dependence upon the status of the microtubule tip. Since the tip can now have four
different states, the attachment process (i) to microtubule k occurs at rate
λNT
(
(vk0 + p(1− vk0))(1− wk0) + r(vk0 + p(1− vk0))wk0
)
, (2)
where the dimensionless non-negative constant r modulates the attachment propensity
compared to the drug-free tip, see Equation (1). Small values of r would mean that
attachment of new GTP tubulin units is hindered by drug molecules bound to the
tip. On the other hand, values r > 1 would increase microtubule polymerization. The
shrinking reactions (ii) and (iii) occur at rates
µGDP (1− vk0)((1− wk0) + qwk0), and µGTPvk0((1− wk0) + qwk0), (3)
where a small value of q ≥ 0 implies a high level of protection afforded by a drug molecule
bound to the tip. If a drug bound tubulin can fall off a microtubule (i.e. if q > 0), then
the drug-tubulin compound is assumed to dissociate immediately. We refer to Figure 1
for the possible interactions of the drug with the microtubules (as implemented in this
paper).
There are also possible drug actions beyond the microtubule tips. As was first
discovered by Lin and Hamel [30], a drug can also inhibit the hydrolysis of bound GTP
tubulin. This can be implemented by “splitting” the scalar and vectorial hydrolysis
reactions (iv) and (v). More precisely, let I0(v
k) and I1(v
k) be the number of GTP
tubulin units within the microtubule word vk that are unoccupied respectively occupied
by a drug molecule. Then the scalar hydrolysis reactions (iv0) and (iv1) occur at rates
δsc
∑m
k=1 I0(v
k) (as before) and sδsc
∑m
k=1 I1(v
k) (with 0 ≤ s ≤ 1). A similar splitting is
used for the vectorial hydrolysis reaction (v).
3. Materials and Methods
Tubulin (15µM), phosphocellulose purified, MAP-free, was assembled on the ends of
sea urchin (Strongylocentrotus purpuratus) axoneme fragments at 30◦C in 87mmol/L
Pipes, 36mmol/L Mes, 1.4mmol/L MgCl2, 1mmol/L EGTA, pH 6.8 (PMME
buffer) containing 2mmol/L GTP for 30 min to achieve steady state. We used
a 100nmol/L concentration of S-methyl-D-DM1 (N2
′
-deacetyl-N2
′
-(3-thiomethyl-1-
oxopropyl)-D-maytansine [31], see Figure 2, right panel), which had no considerable
effect on microtubule polymer mass, to analyze their individual effects on dynamic
instability. Time-lapse images of microtubule plus ends were obtained at 30◦C by
video-enhanced differential interference contrast microscopy at a spatial resolution
of 0.3µm using an Olympus IX71 inverted microscope with a 100 × oil immersion
objective (NA = 1.4). The end of an axoneme that possesses more, faster growing, and
longer microtubules than the other end was designated as the plus end as described
previously [32, 33]. Microtubule dynamics were recorded for 40 min at 30◦C, capturing
∼ 10min long videos for each area under observation. The microtubules were tracked
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approximately every 3 s using RTMII software, and the life-history data were obtained
using IgorPro software (MediaCybernetics, Bethesda, MD) [34].
We have programmed the reactions (i)–(viii) using the Gillespie Algorithm [21] (in
Java, available from the corresponding author upon request). This algorithm simulates
the chemical reactions as collisions of particles in real time and its parameters are the
actual reaction rates, not probabilities. If the empty word is reached, then a new
microtubule is created (a word containing a single GTP tubulin unit). The gain in
length due to addition of a single tubulin unit is taken to be ` = 8nm/13 = 0.6nm; see
e.g. [8, Equation (2)].
4. Results
Results of the in vitro experiments are shown in Figures 3 and 7. During periods of
growth, the untreated microtubules grow at a velocity of ≈ 3µmmin−1 while during
periods of shrinkage, microtubules shrink at ≈ 20µmmin−1. While they are infrequent,
we attribute occasional periods of stagnation to the spatial resolution of the microscope
of approximately 400 tubulin dimer units.
The left panels of Figures 4, 5 and 6 show possible simulations of the control
scenario in the absence of drugs. The choice of appropriate parameter values for the
simulations is a difficult problem, since different values have been reported in different
literature sources and some parameters have only been estimated on the basis of the
Arrhenius Equation (see [14, Table 1] for some ranges). While there is no unique
choice of parameter values, we observe a good agreement of the simulated and observed
growth and shrinking velocities, for the choice of parameter values in Table 1, see Figure
4. To quantify the agreement between the simulations and the experimental data we
used the absolute Fourier spectra [35] of the length time series. We first re-sampled
both the experimental data and the numerical simulations on equispaced time grids at
approximately 0.4Hz. In order to make different simulations comparable, we subtracted
the mean from each length time series so that the resulting normalized lengths have mean
zero. If ln, n = 0, . . . , N − 1 are the re-sampled normalized lengths, then the discrete
Fourier transform is given by the absolute values of
Lk =
N−1∑
n=0
ln exp
(
−2piikn
N
)
, k = 0, . . . , N − 1.
This is conveniently done with the help of the fast Fourier transform routine fft in
scilab‡. Results are shown in the right panels of Figures 3 and 4, showing a good
agreement among experimental and simulated data of the location and the height of the
peak of the averaged spectra. In Figure 6, a sensitivity check is run with significantly
larger parameter values λ = 1.0 (`s)−1, µGDP = 2000 s−1, δsc = δvec = 3.0 (`s)−1 and
κ = 0.5 s−1, see Table 1 for comparison. As a result, higher oscillation frequencies
would be expected in the Fourier spectra due to higher rate of polymerization,
‡ Open source software; available at www.scilab.org.
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depolymerization, hydrolysis and recycling events. This is clearly shown in the right
panel of Figure 6, as the spectrum visibly shifts towards higher frequencies.
The presence of the drug clearly decelerates the dynamic activity of the
microtubules as can be seen from Figure 7. This is also visible in the reduced peak
heights of the Fourier spectra, while the position of the peak, i.e. the main frequency
of the oscillations remains unchanged, at least not discernible on the 0.4Hz frequency
grid, see also Figure 9. With the same parameter values as in the control in Figure 4,
we simulated the presence of a microtubule-binding drug that suppresses strongly the
addition of new GTP tubulin (r = 0.01), completely inhibits the loss of tubulin at the
tip (q = 0) and does not affect the hydrolysis of bound GTP tubulin (s = 1). The
open drug binding sites are all entries 0 in the drug words. The results are shown in
Figure 8. There are 400 drug molecules present in the simulation (compared to ≈ 105
tubulin units). This amount of roughly 100 drug molecules per microtubule matches
approximately the concentration of S-methyl-D-DM1 in the experiments.
The nonlocal drug action mechanism where the bound drug inhibits hydrolysis of
GTP tubulin is much less effective in suppressing microtubule dynamic instability. In
Figure 10 we show simulations of 5 microtubules built of approximately 105 tubulin
units in the presence of a drug that completely inhibits hydrolysis reactions (iv) and
(v), i.e. s = 0 without affecting the binding and loss reactions, r = q = 1. We observe
that a much higher amount of drug, namely of the order of tubulin units, is required to
have any visible effect, while at the same time, long periods of shortening still occur.
In order to better understand the influence of a drug acting at the microtubule
tip, we systematically varied the parameters r and q, keeping all other parameters and
the drug concentration constant. We consider the reduction of the peak height of the
absolute Fourier spectra relative to the control scenario. If the drug molecules are free to
bind any of the open drug binding sites, then a complete repression of the loss reactions
(ii) and (iii), i.e. q = 0 is required to efficiently suppress the dynamic instability of
microtubules, see Figure 11, left panel. An alternative is to allow drug molecules to
bind only at the tip [33]. In that case, the suppression effect persists for weaker drug
effects (Figure 11, right panel). However, it is still more important to suppress the loss
reactions (small value of q) than to suppress the growth reaction (r ≈ 1 is admissible).
Notice that these predictions of the model are drawn from the shapes of the surfaces in
Figure 11, not from particular values.
5. Discussion
Spatial and temporal regulation of the dynamic instability of microtubules is essential
to carry out several vital cellular functions. In cells, the dynamicity of microtubules
is regulated by a number of proteins such as MAPs [11], G proteins [36], and the
plus end tracking proteins, including EB1 [11]. Perturbations in the innate dynamicity
of microtubules induce cell cycle arrest and thereby inhibit cell proliferation. Thus,
compounds that target microtubules are potential anticancer drugs. Our recent studies
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have found synthetic derivatives of maytansine such as DM1 (for drug maytansinoid 1)
that can be conjugated to tumor-specific antibodies as potent suppressors of microtubule
dynamics [25, 33]. Antibody-DM1 Conjugates are under clinical evaluation, and they
show promising early results. Thus, the synthetic derivative of maytansine S-methyl-D-
DM1 is a good example to complement our modeling studies.
In this paper we have presented a detailed reaction scheme for microtubule
polymerization, GTP tubulin hydrolysis, catastrophic shrinking, recycling and
interaction with tubulin-binding drugs. Our in silico simulations show good agreement
of Fourier spectra with experimental data of growing microtubules under control
conditions and treated with the maytansine derivative S-methyl-D-DM1. Our model
allows to accommodate a wide variety of drug binding mechanisms and interactions of
the drug with the normal microtubule polymerization and depolymerization processes.
We find that drugs that act at the microtubule tip by inhibiting addition of GTP tubulin
and loss of GDP tubulin are effective suppressors of microtubule dynamic instability.
This would also be the action mechanism of S-methyl-D-DM1. Among these two actions,
the inhibition of the loss of GDP tubulin is more important than the inhibition of the
growth reaction. A localized binding to the tip inhibits dynamic instability even more.
On the other hand, drugs whose action is to inhibit hydrolysis of bound GTP tubulin
need to be present at numbers comparable to the number of tubulin units to have a
visible effect on microtubule dynamic instability.
Our assumption in modeling the drug binding reaction (vii) has been that either
the drug molecule binds to any open binding site with equal probability or that it binds
only at an open site at the tip. The former is the binding mode of a drug like paclitaxel
that stabilizes a microtubule along its entire length. Other drugs, such as vinblastine
bind with high affinity only at the microtubule plus end [22]. In future work we will
implement a probability of drug binding that decreases with increasing distance from
the tip.
It is well known that some drugs have different effects at different concentrations.
For example, taxol (paclitaxel) increases microtubule polymerization at high
concentrations (50 taxol molecules per 100 tubulin molecules), while it reduces the
rate of shortening at low concentrations (1 taxol molecule per 100 tubulin molecules)
[22]. This suggests the need for a “nonlocal” generalization of the perturbation of the
binding and shrinking processes, in contrast to the present choices in Equations (2) and
(3).
The design of therapeutic drugs requires long and tedious searches among all
possible binding sites on the target. Identifying the most favorable binding site (with the
lowest binding energy), however, is needed to design or discover a drug compound with
the highest possible efficacy. Information on drug-ligand binding affinities (for tubulin
and tubulin-binding drugs in particular) can be extracted by careful comparison of
simulation results and experimental data. Such estimations of binding energies will be
addressed in a future study.
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6. Tables and Figures
parameter value remark reference
λ 0.4 (`s)−1 addition rate of GTP tubulin to GTP tip [16]
p 0.05 reduction of GTP addition to GDP tip [16]
µGDP 800 s
−1 loss of GDP tubulin from tip [3]
µGTP 1.5 s
−1 loss of GTP tubulin from tip [8, 28]
δsc 1.2 (`s)
−1 rate of scalar hydrolysis [8]
δvec 1.2 (`s)
−1 rate of vectorial hydrolysis [8]
κ 0.1 s−1 rate of GDP tubulin recycling [37]
L 6 average GTP tubulin addition size [27]
ρ 1.0s−1 rate of drug binding
σ 0.1 s−1 rate of drug release
Table 1. Baseline values of parameters used in the stochastic simulations. Here
` = 0.6nm is the gain in length by addition of a single tubulin unit. The references
provide further discussion and sometimes comparable values.
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Figure 1. The reactions and possible drug interactions implemented in our stochastic
model. A drug may also promote polymerization and depolymerization.
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Figure 2. (Left panel) Schematic depiction of the two hydrolysis mechanisms. The
scalar hydrolysis reaction (p. 4 (iv), top) picks a random bound GTP tubulin and
changes it into a bound GDP tubulin. The vectorial hydrolysis reaction (p. 5 (v),
bottom) occurs at a boundary between a GDP zone and a GTP zone. (Right panel)
Structural formula of the maytansine analog S-methyl-D-DM1.
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Figure 3. (Left panel) Length time series of 10 microtubules in absence of drug.
Notice that life histories from several experiments are plotted in the same diagram.
(Right panel) Absolute Fourier spectra of the control experimental data that were
normalized to mean length zero. The thick blue line is the average of the 10 individual
spectra.
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Figure 4. (Left panel) Simulation of m = 5 microtubules starting from random
initial states, with a total of ≈ 105 tubulin units. The parameter values are as in
Table 1. GTP tubulin is added in the form of oligomers whose length is Poisson
distributed with with mean L = 6. The resulting average growth velocity during
periods of growth is approximately 2µmmin−1 while the resulting shrinking velocity is
approximately 20µmmin−1. (Right panel) Absolute Fourier spectra of the simulation
data, normalized to mean length zero. The thick blue line is the average of the 5
individual spectra.
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Figure 5. (Left panel) Simulation of m = 5 microtubules with parameter values as
in Table 1 and Figure 4 except that GTP tubulin is added in units of fixed length
L = 1. (Right panel) Absolute Fourier spectra of the simulation data, normalized to
mean length zero and their average.
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Figure 6. (Left panel) Simulation of m = 5 microtubules with parameter values
λ = 1.0 (`s)−1, µGDP = 2000 s−1, δsc = δvec = 3.0 (`s)−1 and κ = 0.5 s−1, all of which
are larger than those in Table 1. (Right panel) The corresponding absolute Fourier
spectra show a visible shift towards higher frequencies.
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Figure 7. (Left panel) Length time series of 10 microtubules in presence of the drug S-
methyl-D-DM1. (Right panel) The corresponding absolute Fourier spectra, normalized
to mean length zero. The thick blue line is the average of the 10 individual spectra.
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Figure 8. (Left panel) Simulation of m = 5 microtubules in the presence of 400 drug
molecules, with a total of ≈ 105 tubulin units. The parameter values are as in Figure
4, in addition r = 0.01, q = 0 and s = 1. Here the drug molecules bind to any open
site with equal probability. (Right panel) The corresponding absolute Fourier spectra.
This simulation suggests a possible action mechanism for the drug S-methyl-D-DM1.
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Figure 9. Detail of the average absolute Fourier spectra from Figures 3, 4, 7 and 8.
Within the resolution of the frequency grid ≈ 0.11min−1, there is no discernible shift
of the position of the peaks.
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Figure 10. Simulation of m = 5 microtubules with a total of ≈ 105 tubulin units
in the presence a drug that completely inhibits GTP tubulin hydrolysis. The relevant
parameter values are r = q = 1 and s = 0. The total amount of drug is 20000 (left
panel) respectively 40000 (right panel).
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Figure 11. The reduction of microtubule dynamic instability relative to the untreated
case as the drug effects vary. Shown are the relative peak heights of the averaged
absolute Fourier spectra of 20 microtubules at a concentration of 100 drug molecules
for every microtubule. The drug molecules bind either at any open site along the
microtubule (left panel) or at the tip only (right panel). The drug does not affect the
hydrolysis of bound GTP tubulin (s = 1).
